Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 7/20 | 0.45 |
| ▸ | CDK4 | P11802 | 6/20 | 0.45 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | COMT | P21964 | 9/20 | 0.44 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | CDK7 | P50613 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.38 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.37 |
| ▸ | PLK1 | P53350 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15507434 | 0.70 | TTK (0.45) | CDK2CDK4CCNE1LMNAHTT | |
| SCHEMBL21871437 | 0.69 | SMN1; SMN2 (0.46) | HTT | |
| SCHEMBL28776134 | 0.69 | CDK2 (0.66) | CDK2CDK4CCNE1LMNAHTT | |
| SCHEMBL5318384 | 0.68 | CDK4 (0.45) | CDK2CDK4CCNE1LMNAHTT | |
| SCHEMBL12537263 | 0.67 | COMT (0.52) | CDK2CDK4CCNE1LMNAHTT | |
| SCHEMBL2090003 | 0.67 | COMT (0.42) | CDK2CDK4CCNE1LMNAHTT | |
| SCHEMBL1781026 | 0.66 | CDC7 (0.39) | CDK7CDK9 | |
| SCHEMBL7220708 | 0.66 | LMNA (0.53) | CDK2CDK4CCNE1LMNAHTT | |
| SCHEMBL15051745 | 0.64 | GRM5 (0.40) | CDK7CDK9 | |
| SCHEMBL16434004 | 0.64 | LMNA (0.72) | LMNAHTTTRPV4OPRM1NR2F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070155764-A1 | NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES | KALYPSYS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070155764-A1 | NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES | KALYPSYS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070155764-A1 | NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES | KALYPSYS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| WO-2007076473-A2 | SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES | KALYPSYS, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155764-A1 | NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES | BRAF, ARAF, RAF1 | CDK2 8/4885CDK4 57/4885CCNE1 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.